A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): Discovery of (S)- 2-(8-(Methoxycarbonylamino)dibenzo[b,d]furan- 3-sulfonamido)-3-methylbutanoic acid (MMP408)

Journal of Medicinal Chemistry

Volumn 52, Issue 7, 2009, Pages 1799-1802

  Wei, Li ^a   Jianchang, Li ^a   Yuchuan, Wu ^a   Junjun, Wu ^a   Hotchandani, Rajeev ^a   Cunningham, Kristina ^a   McFadyen, Iain ^a   Bard, Joel ^a   Morgan, Paul ^a   Schlerman, Franklin ^a   Xin, Xu ^a   Tam, Steve ^a   Goldman, Samuel J ^a   Williams, Cara ^a   Sypek, Joseph ^a   Mansour, Tarek S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [8 (METHOXYCARBONYLAMINO)DIBENZO[B,D]FURAN 3 SULFONAMIDO) 3 METHYLBUTANOIC ACID; ENZYME INHIBITOR; MACROPHAGE ELASTASE; MMP 408; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG BIOAVAILABILITY; ENZYME INHIBITION; MOLECULAR MODEL; NONHUMAN;

ANIMALS; BENZOFURANS; BIOLOGICAL AVAILABILITY; HAPLORHINI; HUMANS; MATRIX METALLOPROTEINASE 12; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; RECOMBINANT PROTEINS; SHEEP; SPECIES SPECIFICITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 64549096788     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900093d     Document Type: Article

References (19)

1. Pauwels, R. A.; Rabe, K. F. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004, 364, 613-620.
2. Skrepnek, G. H.; Skrepnek, S. T. Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. Am. J. Managed Care 2004, 10, S129-S138.
3. Tashkin, D. P.; Celli, B.; Senn, S.; Burkhart, D.; Kesten, S.; Menjoge, S.; Decramer, M. A 4-tear trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008, 359, 1543-1554.
4. Belvisi, M. G.; Hele, D. J.; Birell, M. A. New anti-inflammatory therapies and targets for asthma and chronic obstructive pulmonary disease. Expert Opin. Ther. Targets 2004, 8, 265-285.
5. Bergeron, C.; Boulet, L. Structural changes in airway diseases. characteristics, mechanisms, consequences, and pharmacologic modulation. Chest 2006, 129, 1068-1087.
6. Lagente, V.; Manoury, B.; Nenan, S.; le Quement, C.; Martin-Chouly, C.; Boichot, E. Role of matrix metalloproteinases in the devlopment of airway inflammation and remodeling. Braz. J. Med. Biol. Res. 2005, 38, 1521-1530.
7. Shapiro, S. D.; Kobayashi, D. K.; Ley, T. J. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J. Biol. Chem. 1993, 26, 23824-23829.
8. Hautamaki, R. D.; Kobayashi, D. K.; Senior, R. M.; Shapiro, S. D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997, 277, 2002-2004.
9. Leclerc, O.; Lagente, V.; Panquois, J.; Berthelier, C.; Artola, M.; Eichholtz, T.; Bertrand, C. P.; Schmidlin, F. Involvement of MMP- 12 and phosphodiesterase type 4 in cigarette smoke-induced inflammtion in mice. Eur. Respir. J. 2006, 27, 1102-110.
10. Churg, A.; Wang, R. D.; Tai, H.; Wang, X.; Xie, C.; Dai, J.; Shapiro, S. D.; Wright, J. L. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-a release. Am. J. Respir. Crit. Care Med. 2003, 167, 1083-1089.
11. Wu, J.; Rush, T. S.; Hotchandani, R.; Du, X.; Geck, M.; Collins, E.; Xu, Z. B.; Skotnicki, J.; Levin, J. I.; Lovering, F. E. Identification of potent and selective MMP-13 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 4105-4109.
12. Markus, M. A.; Dwyer, B.; Wolfrom, S.; Li, J.; Li, W.; Malakian, K.; Wilhelm, J.; Tsao, D. H. H. Solution structure of wild-type human matrix metalloprotease 12 (MMP-12) in complex with a tight-binding inhibitor. J. Biomol. NMR 2008, 41, 55-60.
13. Hu, Y.; Xiang, S.; DiGrandi, M. J.; Du, X.; Ipek, M.; Laakso, L. M.; Li, J.; Li, W.; Rush, T. S.; Schmid, J.; Skotnicki, J. S.; Tam, S.; Thomason, J. R.; Wang, Q.; Levin, J. I. Potent, selective and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg. Med. Chem. 2005, 13, 6629-6644.
14. Li, J.; Rush, T. R.; Li, W.; DeVincentis, D.; Du, X.; Hu, Y.; Thomason, J. R.; Xiang, S.; Skotnicki, J. S.; Tam, S.; Cunningham, K. M.; Chockalingam, P. S.; Morris, E. A.; Levin, J. I. Synthesis and SAR of highly selective MMP-13 inhibitor. Bioorg. Med. Chem. Lett. 2005, 15, 4961-4966.
15. ForDBFas a scaffold forPDE4inhibitors, see the following: Kodimuthali, A.; Jabaris, S. S. L.; Pal, M. Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. J. Med. Chem. 2008, 51, 5471-5489, and references cited therein. For MMP inhibitors, see the following:O'Brien, P. M.; Picard, J. A.; Sliskovic, D. R.; White, A. D. Method of Inhibiting Matrix Metalloproteases. U.S. Patent 6906092, 2005.
16. Takashi Keumi, T.; Tomioka, N.; Hamanaka, K.; Kakihara, H.; Fukushima, M.; Morita, T.; Kitajima, H. Positional reactivity of dibenzofuran in electrophilic substitutions. J. Org. Chem. 1991, 56, 4671-4677.
17. Mitsumori, S.; Tsuri, T.; Honma, T.; Hiramatsu, Y.; Okada, T.; Hashizume, H.; Inagaki, M.; Arimura, A.; Yasui, K.; Asanuma, F.; Kishino, J.; Ohtani, M. Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 1. Bicyclo[2.2.1]heptane derivatives. J. Med. Chem. 2003, 46, 2436-2445.
18. Nenan, S.; Lagente, V.; Planquois, J.; Hitier, S.; Berna, P.; Bertrand, C. P.; Biochot, E. Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur. J. Pharmacol. 2007, 559, 75-81.
19. Li, W.; Li, J.; Wu, Y.; Tam, S.; Mansour, T. S.; Sypek, J. P.; Mcfayden, I.; Hotchandani, R.; Wu, J. Preparation of Tricyclic Compounds as Matrix Metalloprotease Inhibitors. PCT Int. Appl. WO 2008057254 A2, 2008.